+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-infective Agents Market Size, Share & Trends Analysis Report By Type/Drug Class (Antivirals, Antifungals), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 4761213
Description Jump to:
The global anti-infective agents market size is expected to reach USD 150.6 billion by 2030, registering a CAGR of 1.2% from 2023 to 2030. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Anti-infective Agents Market Report Highlights

  • Antiviral was estimated to be the largest segment with a market share of 53.2% in 2022 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
  • Antibacterial segment is anticipated to register the fastest CAGR of 4.2% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
  • Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
  • Oral route of administration was estimated to be the held largest segment in 2022 owing to new product development and presence of strong product pipeline
  • Hospital pharmacy dominated the market with the highest revenue share of 28.8% in 2022 while e-commerce is expected to be the fastest-growing segment during the forecast period
  • North America dominated the global industry in 2022 and accounted for the largest share of 37.0% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
  • Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
  • Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Route of Administration
1.1.3. Distribution Channel
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary route of administrations
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Route of administration outlook
2.2.3. Distribution channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Anti-Infective Agents Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Anti-Infective Agents Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic Landscape
Chapter 4. Anti-Infective Agents: Type/Drug Class Estimates & Trend Analysis
4.1. Anti-Infective Agents Market: Key Takeaways
4.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Antibacterials
4.3.1. Antibacterials market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2. Antibacterials drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.1. Cephalosporins
4.3.2.1.1 Cephalosporins market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.2. Penicillin
4.3.2.2.1 Penicillin market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.3. Fluoroquinolones
4.3.2.2.2 Fluoroquinolones market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.3 Macrolides
4.3.2.3.1 Macrolides market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.4 Carbapenem
4.3.2.4.1 Carbapenem market estimates and forecasts, 2018 to 2030 (USD Billion)
4.3.2.5 Others
4.3.2.5.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)
4.4. Antivirals
4.4.1. Antivirals market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5. Antifungals
4.5.1. Antifungals market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2. Antifungals drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.1. Azoles
4.5.2.1.2 Azoles market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.2. Echinocandins
4.5.2.2.3 Echinocandins market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.3. Polyenes
4.5.2.2.4 Polyenes market estimates and forecasts, 2018 to 2030 (USD Billion)
4.5.2.3 Others
4.5.2.3.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 5. Anti-Infective Agents Market: Route of Administration Estimates & Trend Analysis
5.1. Anti-Infective Agents Market: Key Takeaways
5.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Topical
5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Billion)
5.4. Oral
5.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Billion)
5.5. IV
5.5.1. IV market estimates and forecasts, 2018 to 2030 (USD Billion)
5.6. Others
5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 6. Anti-Infective Agents Market: Distribution Channel Estimates & Trend Analysis
6.1. Anti-Infective Agents Market: Key Takeaways
6.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Hospital Pharmacies
6.3.1. Hospital pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
6.4. Retail Pharmacies
6.4.1. Retail pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
6.5. Specialty Pharmacies
6.5.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
6.6. E-Commerce
6.6.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
6.7. Others
6.7.1. Other market estimates and forecasts, 2018 to 2030 (USD Billion)
Chapter 7. Anti-Infective Agents Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Anti-Infective Agents Market by Region: Key Takeaways
7.3. North America
7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.7.2. Saudi Arabia
7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. Pfizer Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Abbott.
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Gilead Sciences, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Bristol-Myers Squibb Company
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Merck & Co., Inc.
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Sandoz International GmbH
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. B. Braun SE
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Xellia Pharmaceuticals
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Mankind Pharma
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Bayer AG
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. AstraZeneca
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Boehringer Ingelheim International GmbH.
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 3 North America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 4 North America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 5 North America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
Table 6 U.S. anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 7 U.S. anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 8 U.S. anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 9 Canada anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 10 Canada anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 11 Canada anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 12 Europe anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 13 Europe anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 14 Europe anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 15 Europe anti-infective agents market, by region, 2018 - 2030 (USD Billion)
Table 16 Germany anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 17 Germany anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 18 Germany anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 19 UK anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 20 UK anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 21 UK anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 22 France anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 23 France anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 24 France anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 25 Italy anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 26 Italy anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 27 Italy anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 28 Spain anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 29 Spain anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 30 Spain anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 31 Sweden anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 32 Sweden anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 33 Sweden anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 34 Norway anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 35 Norway anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 36 Norway anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 37 Denmark anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 38 Denmark anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 39 Denmark anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 40 Asia Pacific anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 41 Asia Pacific anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 42 Asia Pacific anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 43 Asia Pacific anti-infective agents market, by region, 2018 - 2030 (USD Billion)
Table 44 Japan anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 45 Japan anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 46 Japan anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 47 China anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 48 China anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 49 China anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 50 India anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 51 India anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 52 India anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 53 Australia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 54 Australia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 55 Australia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 56 Thailand anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 57 Thailand anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 58 Thailand anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 59 South Korea anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 60 South Korea anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 61 South Korea anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 62 Latin America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 63 Latin America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 64 Latin America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 65 Latin America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
Table 66 Brazil anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 67 Brazil anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 68 Brazil anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 69 Mexico anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 70 Mexico anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 71 Mexico anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 72 Argentina anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 73 Argentina anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 74 Argentina anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 75 Middle East and Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 76 Middle East and Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 77 Middle East and Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 78 Middle East and Africa anti-infective agents market, by region, 2018 - 2030 (USD Billion)
Table 79 South Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 80 South Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 81 South Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 82 Saudi Arabia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 83 Saudi Arabia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 84 Saudi Arabia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 85 UAE anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 86 UAE anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 87 UAE anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
Table 88 Kuwait anti-infective agents market, by type, 2018 - 2030 (USD Billion)
Table 89 Kuwait anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
Table 90 Kuwait anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Anti-infective agents: Market outlook
Fig. 9 Anti-infective agents: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Anti-infective agents market driver impact
Fig. 15 Anti-infective agents market restraint impact
Fig. 16 Anti-infective agents market strategic Initiatives analysis
Fig. 17 Anti-infective agents market: Type movement analysis
Fig. 18 Anti-infective agents market: Type outlook and key takeaways
Fig. 19 Antibacterials market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 20 Antibacterials drug class market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 21 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 22 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 23 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 24 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 25 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 27 Antivirals market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 28 Antifungals market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 29 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 30 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 31 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 32 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 33 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 35 Anti-infective agents market: Route of administration movement analysis
Fig. 36 Anti-infective agents market: Route of administration outlook and key takeaways
Fig. 37 Topical market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 38 Oral market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 39 IV market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 41 Anti-infective agents market: Distribution channel movement analysis
Fig. 42 Anti-infective agents market: Distribution channel outlook and key takeaways
Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 44 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 45 Specialty pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 46 E-commerce market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 47 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 48 Global anti-infective agents market: Regional movement analysis
Fig. 49 Global anti-infective agents market: Regional outlook and key takeaways
Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 53 Europe. market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 63 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 65 India market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 66 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 67 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 69 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 70 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 71 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 72 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 73 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 75 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)

Companies Mentioned

  • Pfizer Inc.
  • Abbott.
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sandoz International GmbH
  • B. Braun SE
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • Bayer AG
  • AstraZeneca
  • Boehringer Ingelheim International GmbH.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 136.9 Billion
Forecasted Market Value ( USD ) by 2030 $ 150.6 Billion
Compound Annual Growth Rate1.2%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Anti-infective Agents Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028 - Product Image

Anti-infective Agents Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2018-2028

  • Report
  • 188 Pages
  • Global
From
Global Anti-Infective Market Report and Forecast 2023-2031 - Product Image

Global Anti-Infective Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Anti-Infective Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031 - Product Image

Anti-Infective Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031

  • Report
  • 118 Pages
  • Global
From
Anti-infective Agents Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Anti-infective Agents Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 73 Pages
  • Global
From
Anti-Infectives: Global Strategic Business Report - Product Image

Anti-Infectives: Global Strategic Business Report

  • Report
  • 116 Pages
  • Global
From

About the Infection Drug Market

The Infectious Diseases Drugs market is a subset of the pharmaceutical industry that focuses on the development and production of drugs used to treat infectious diseases. These drugs are used to treat a wide range of infections, including bacterial, viral, fungal, and parasitic infections. The market is highly competitive, with many companies vying for market share. Companies in the market are typically focused on developing new drugs, as well as improving existing treatments. Additionally, many companies are involved in the production of generic drugs, which are often cheaper than brand-name drugs. Companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.